<SEC-DOCUMENT>0001104659-22-097701.txt : 20220906
<SEC-HEADER>0001104659-22-097701.hdr.sgml : 20220906
<ACCEPTANCE-DATETIME>20220906081050
ACCESSION NUMBER:		0001104659-22-097701
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20220905
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220906
DATE AS OF CHANGE:		20220906

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Synthetic Biologics, Inc.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133808303
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12584
		FILM NUMBER:		221226933

	BUSINESS ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		(734) 332-7800

	MAIL ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADEONA PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PIPEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20061214

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SHEFFIELD PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19970730
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2225140d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:syn="http://syntheticbiologics.com/20220905">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_037_syn_syntheticbiologics.com_20220905 -->
<!-- Field: Set; Name: xdx; ID: xdx_04A_20220905_20220905 -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DEntityCentralIndexKey_0000894158 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-09-05to2022-09-05" name="dei:EntityCentralIndexKey">0000894158</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-09-05to2022-09-05" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="syn-20220905.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-09-05to2022-09-05">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-09-05</xbrli:startDate>
        <xbrli:endDate>2022-09-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>WASHINGTON, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_90B_edei--DocumentType_c20220905__20220905_z1eOb0Lpe9Se"><ix:nonNumeric contextRef="From2022-09-05to2022-09-05" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 or 15(d)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>of the Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Date of Report (Date of earliest event
reported): <span id="xdx_90F_edei--DocumentPeriodEndDate_c20220905__20220905_zVFFprOSR6Q8"><ix:nonNumeric contextRef="From2022-09-05to2022-09-05" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">September 5, 2022</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90C_edei--EntityRegistrantName_c20220905__20220905_zF77VBK8qhm4"><ix:nonNumeric contextRef="From2022-09-05to2022-09-05" name="dei:EntityRegistrantName">SYNTHETIC BIOLOGICS, INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; width: 32%; padding-right: 0.8pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_904_edei--EntityIncorporationStateCountryCode_c20220905__20220905_z9j2fdjg0fxf"><ix:nonNumeric contextRef="From2022-09-05to2022-09-05" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></b></span></td>
    <td style="width: 1%; padding-right: 0.8pt; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 34%; padding-right: 0.8pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_900_edei--EntityFileNumber_c20220905__20220905_zSnGwqCXlWDf"><ix:nonNumeric contextRef="From2022-09-05to2022-09-05" name="dei:EntityFileNumber">001-12584</ix:nonNumeric></span></b></span></td>
    <td style="width: 1%; padding-right: 0.8pt; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 32%; padding-right: 0.8pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90A_edei--EntityTaxIdentificationNumber_c20220905__20220905_zg0Akrhk7Sa3"><ix:nonNumeric contextRef="From2022-09-05to2022-09-05" name="dei:EntityTaxIdentificationNumber">13-3808303</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction of</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">incorporation)</p></td>
    <td style="padding-right: 0.8pt; text-align: center">&#160;</td>
    <td style="padding-right: 0.8pt; text-align: center"><span style="font-size: 10pt">(Commission File No.)</span></td>
    <td style="padding-right: 0.8pt; text-align: center">&#160;</td>
    <td style="padding-right: 0.8pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(IRS Employer Identification</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">No.)</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90B_edei--EntityAddressAddressLine1_c20220905__20220905_zQDIHrugZNPi"><ix:nonNumeric contextRef="From2022-09-05to2022-09-05" name="dei:EntityAddressAddressLine1">9605 Medical Center Drive</ix:nonNumeric></span>, <span id="xdx_907_edei--EntityAddressAddressLine2_c20220905__20220905_z85M8kAo9Ch5"><ix:nonNumeric contextRef="From2022-09-05to2022-09-05" name="dei:EntityAddressAddressLine2">Suite 270</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90A_edei--EntityAddressCityOrTown_c20220905__20220905_zea2Q5aI5Hg6"><ix:nonNumeric contextRef="From2022-09-05to2022-09-05" name="dei:EntityAddressCityOrTown">Rockville</ix:nonNumeric></span>, <span id="xdx_90D_edei--EntityAddressStateOrProvince_c20220905__20220905_zJJwzchHwise"><ix:nonNumeric contextRef="From2022-09-05to2022-09-05" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">Maryland</ix:nonNumeric></span> <span id="xdx_905_edei--EntityAddressPostalZipCode_c20220905__20220905_z8Cj0YQc7fi7"><ix:nonNumeric contextRef="From2022-09-05to2022-09-05" name="dei:EntityAddressPostalZipCode">20850</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices and zip
code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(<span id="xdx_902_edei--CityAreaCode_c20220905__20220905_zKCsiychaNB6"><ix:nonNumeric contextRef="From2022-09-05to2022-09-05" name="dei:CityAreaCode">301</ix:nonNumeric></span>) <span id="xdx_90D_edei--LocalPhoneNumber_c20220905__20220905_zkokce8Wr1U3"><ix:nonNumeric contextRef="From2022-09-05to2022-09-05" name="dei:LocalPhoneNumber">417-4364</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&#8217;s telephone number, including
area code</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>N/A</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed since
last report)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font: 10pt Wingdings"><span id="xdx_90A_edei--WrittenCommunications_c20220905__20220905_zfnQ2C6o1Av2"><ix:nonNumeric contextRef="From2022-09-05to2022-09-05" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font: 10pt Wingdings"><span id="xdx_900_edei--SolicitingMaterial_c20220905__20220905_zT2BugI0p9L9"><ix:nonNumeric contextRef="From2022-09-05to2022-09-05" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font: 10pt Wingdings"><span id="xdx_90D_edei--PreCommencementTenderOffer_c20220905__20220905_zQLwRr9HBqo7"><ix:nonNumeric contextRef="From2022-09-05to2022-09-05" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font: 10pt Wingdings"><span id="xdx_903_edei--PreCommencementIssuerTenderOffer_c20220905__20220905_ztv3Zv4sbArh"><ix:nonNumeric contextRef="From2022-09-05to2022-09-05" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered pursuant to Section 12(b)
of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border: black 1pt solid; width: 33%; padding-left: 6.4pt; text-align: center"><span style="font-size: 10pt"><b>Title of each class</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 34%; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>Trading Symbol(s)</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 33%; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>Name of each exchange on which<br />
 registered</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 6.4pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_904_edei--Security12bTitle_c20220905__20220905_zYhDWHIE3SW1"><ix:nonNumeric contextRef="From2022-09-05to2022-09-05" name="dei:Security12bTitle">Common stock, par value $0.001 per share</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_908_edei--TradingSymbol_c20220905__20220905_z8yIPrD7xaxa"><ix:nonNumeric contextRef="From2022-09-05to2022-09-05" name="dei:TradingSymbol">SYN</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_908_edei--SecurityExchangeName_c20220905__20220905_zF77Mnutjuhc"><ix:nonNumeric contextRef="From2022-09-05to2022-09-05" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NYSE American</ix:nonNumeric> </span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Emerging growth company&#160;<span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_90E_edei--EntityEmergingGrowthCompany_c20220905__20220905_zLzqoUqv545k"><ix:nonNumeric contextRef="From2022-09-05to2022-09-05" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by checkmark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.&#160;<span style="font-family: Wingdings"><span style="font-family: Wingdings">&#168;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Item 7.01.</b>&#160;&#160;&#160;<b>Regulation
FD Disclosure.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On September 5, 2022,
Synthetic Biologics, Inc. (the &#8220;Company&#8221;) issued a press release announcing a presentation of initial data from a Phase 1
investigator-sponsored study evaluating VCN-01 in combination with durvalumab for patients with recurrent/metastatic squamous cell carcinoma
of the head and neck (R/M HNSCC). Data will be featured in a poster presentation at the European Society for Medical Oncology (ESMO) Congress,
being held both virtually and in Paris from September 9-13, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The information in this
Item 7.01 and in the press release furnished as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be &#8220;filed&#8221;
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section
or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended and shall not be incorporated by reference into any filing with
the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general
incorporation language in such filing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The press release furnished
as Exhibit 99.1 to this Current Report on Form 8-K includes &#8220;safe harbor&#8221; language pursuant to the Private Securities Litigation
Reform Act of 1995, as amended, indicating that certain statements contained therein are &#8220;forward-looking&#8221; rather than historical.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Item 8.01.</b>&#160;&#160;&#160;<b>Other
Events.</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On September 5, 2022,
the Company issued a press release announcing a presentation of initial data from a Phase 1 investigator-sponsored study evaluating VCN-01
in combination with durvalumab for patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC). Data will
be featured in a poster presentation at the European Society for Medical Oncology (ESMO) Congress, being held both virtually and in Paris
from September 9-13, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Key data and conclusions featured in the ESMO presentation include:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td><td style="text-align: justify"><span style="font-size: 10pt"><b>Safety</b>: Treatment with VCN-01 had an acceptable safety profile when administered with durvalumab
in the sequential regimen (single dose of VCN-01 administered 14 days prior to the first dose of durvalumab;</span> n=14<span style="font-size: 10pt">).
</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">o</span></td><td style="text-align: justify">The most common treatment-related adverse events (TRAEs) were pyrexia, flu-like symptoms and increases in liver transaminases.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">o</span></td><td style="text-align: justify">TRAEs were dose-dependent, reversible and consistent with TRAEs previously described for other adenovirus-based products.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><b>Pharmacokinetics (PK) and pharmacodynamics (PD)</b>: Based on toxicology and PK/PD analysis the recommended Phase 2 dose is 1x10<sup>13</sup>
viral particles (vp)/patient.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><b>Biological activity</b>: Sustained blood levels of VCN-01 viral genomes and increased serum hyaluronidase levels were maintained
for over six weeks.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">o</span></td><td style="text-align: justify">Observed an increase in CD8 T cells, a marker of tumor inflammation and an upregulation of PD-L1 in tumors.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">o</span></td><td style="text-align: justify">Analysis of serial tumor biopsies revealed differential gene expression profiles and downregulation of matrix-related pathways after
VCN-01 administration.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Item 9.01. Financial
Statements and Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">(d)</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Exhibits.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 9%; padding-right: 0.8pt; text-align: center"><span style="font-size: 10pt"><b>Exhibit<br />
Number</b></span></td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 90%; padding-right: 0.8pt"><span style="font-size: 10pt"><b>Description</b></span></td></tr>
  <tr>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: center"><a href="tm2225140d1_ex99-1.htm"><span style="font-size: 10pt">99.1</span></a></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><a href="tm2225140d1_ex99-1.htm"><span style="font-size: 10pt">Press Release issued by Synthetic Biologics, Inc., dated September 5, 2022</span></a></td></tr>
  <tr>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: center"><span style="font-size: 10pt">104</span></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><span style="font-size: 10pt">Cover Page Interactive Data File (embedded within the XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the
undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Dated: September 6, 2022</span></td>
    <td colspan="3"><span style="font-size: 10pt">SYNTHETIC BIOLOGICS, INC.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 50%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 5%">&#160;</td>
    <td style="width: 42%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">By:</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid"><span style="font-size: 10pt">/s/ Steven A. Shallcross</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Name:</span></td>
    <td><span style="font-size: 10pt">&#160;Steven A. Shallcross</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Title:</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0">Chief Executive Officer and Chief Financial Officer</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%">&#160;</td><td style="width: 33%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KwjAMhZ9g7xB6LW4d6GSXDhVxyhgi3hYXpbg1I60/eyTf0m5DDIGQnPPlCDERG1rrGhnOyzKHIzZtrRxCiVdkNBf0jmy7S8HPEm/aOlbGDesPzMgz6JnZdKH8fXA+tcUqhWgeyiSMJURJKhMo9iLo9YzMVVdonFY1KFNBwdSyRqe4Gz8c1ZsMNd2QdEK2mkwKchqN8gfiSMZwoKd6Ed8t5HkmgslQgdgwPdo+5mEdNbCqsfFZdkT/HXwB5GpJJA== -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2225140d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><IMG SRC="tm2225140d1_ex99-1img001.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Synthetic Biologics Announces Presentation at
ESMO Congress 2022 Describing Phase 1 Investigator-sponsored Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/
Metastatic Squamous Cell Carcinoma of the Head and Neck </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>-Treatment with VCN-01 in combination with durvalumab
demonstrated an acceptable safety profile and encouraging biological activity-</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: windowtext"><B>Rockville,
MD, September 5, 2022 &ndash; </B></FONT><U>Synthetic Biologics, Inc.</U> <FONT STYLE="color: windowtext">(NYSE American:
SYN),</FONT> a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, <FONT STYLE="color: windowtext">today
announced a presentation of initial data from a Phase 1 investigator-sponsored study evaluating VCN-01 in combination with
durvalumab for patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC). Data will be featured in
a poster presentation at the European Society for Medical Oncology (ESMO) Congress, being held both virtually and in Paris from
September 9-13, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;We
are encouraged by the acceptable safety profile seen in the sequential arm of this study as well as the biological activity observed in</FONT>
R/M HNSCC patients previously treated with anti-PD(L)-1 agents, which speak to the promise of VCN-01-based combination approaches for
devastating cancers with high unmet need,&rdquo; said Manel Cascall&#972;, Ph.D., General Director of Synthetic Biologics&rsquo; European
Subsidiary. &ldquo;Further, these results provide valuable dose-finding context and build upon our compelling foundation of data that
highlight VCN-01&rsquo;s differentiated mechanism of action that may transform cancer therapy. We look forward to leveraging our findings
as we advance VCN-01 through clinical development and we remain on track to deliver on several value-driving milestones, including the
initiation of our Phase 2 study in patients with metastatic pancreatic adenocarcinoma in the fourth quarter of 2022 and our Phase 2/3
study in retinoblastoma in the second half of 2023.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Key data and conclusions featured in the ESMO presentation include:</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Safety</B>: Treatment with VCN-01 had an acceptable safety profile when
administered with durvalumab in the sequential regimen (single dose of VCN-01 administered 14 days prior to the first dose of durvalumab;
n=14). </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">o</TD><TD>The most common treatment-related adverse events (TRAEs) were pyrexia, flu-like symptoms and increases in liver transaminases.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">o</TD><TD>TRAEs were dose-dependent, reversible and consistent with TRAEs previously described for other adenovirus-based products.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Pharmacokinetics (PK) and pharmacodynamics (PD)</B>: Based on toxicology
and PK/PD analysis the recommended Phase 2 dose is 1x10<SUP>13</SUP> viral particles (vp)/patient. </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Biological activity</B>: Sustained blood levels of VCN-01 viral genomes
and increased serum hyaluronidase levels were maintained for over six weeks. </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">o</TD><TD>Observed an increase in CD8 T cells, a marker of tumor inflammation and an upregulation of PD-L1 in tumors.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">o</TD><TD>Analysis of serial tumor biopsies revealed differential gene expression profiles and downregulation of matrix-related pathways after
VCN-01 administration.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
full abstract (#<U>1231P</U></FONT>) is accessible on the <U>ESMO Congress portal</U> and the e-Poster will be available on-demand starting
Saturday, September 10 at 9:00 a.m. CEST. Additional details of the poster are provided below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm2225140d1_ex99-1img001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Title:
                                            Phase I Study to Evaluate the Safety, Tolerability, and Efficacy of VCN-01 in Combination
                                            With Durvalumab (MEDI4736) in Subjects With Recurrent/ Metastatic Squamous Cell Carcinoma
                                            of the Head and Neck (R/M HNSCC)</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Presenting Author: Dr. Ricard Mesia (Head of the Medical Oncology
Department at Institut Catal&agrave; d'Oncologia- Barcelona, Spain)</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Poster Session Date and Time: Monday, September 12 at 12:00 p.m. CEST</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Synthetic Biologics, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Synthetic Biologics, Inc. (NYSE American: SYN) is a diversified clinical-stage
company developing therapeutics designed to treat diseases in areas of high unmet need. The Company advanced into oncology through the
acquisition of VCN Biosciences, S.L. (VCN), who have developed a new oncolytic adenovirus platform designed for intravenous (IV), intravitreal
and antitumoral delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a robust
and sustained anti-tumor response by the patient&rsquo;s immune system. The Company's lead candidates are: (1) VCN-01, an oncolytic adenovirus
designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant
physical and immunosuppressive barrier to cancer treatment; (2) SYN-004 (ribaxamase) which is designed to degrade certain commonly used
IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent (a) microbiome damage, (b) Clostridioides difficile infection
(CDI), (c) overgrowth of pathogenic organisms, (d) the emergence of antimicrobial resistance (AMR), and (e) acute graft-versus-host-disease
(aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and (3) SYN-020, a recombinant oral formulation of the enzyme intestinal
alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases. For more information,
please visit Synthetic Biologics' website at&nbsp;<U>www.syntheticbiologics.com</U>.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>This
release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases
forward-looking statements can be identified by terminology such as &quot;may,&quot; &quot;should,&quot; &quot;potential,&quot; &quot;continue,&quot;
 &quot;expects,&quot; &quot;anticipates,&quot; &quot;intends,&quot; &quot;plans,&quot; &quot;believes,&quot; &quot;estimates,&quot; and
similar expressions, and include statements regarding </I></FONT><I>the promise of VCN-01-based combination approaches for devastating
cancers with high unmet need, VCN-01&rsquo;s differentiated mechanism of action transforming cancer therapy, leveraging findings as VCN-01
is advanced through clinical development, and remaining on track to deliver on several value-driving milestones, including the initiation
of our Phase 2 study in patients with metastatic pancreatic adenocarcinoma in the fourth quarter of 2022 and our Phase 2/3 study in retinoblastoma
in the second half of 2023. These forward-looking statements are based on management's expectations and assumptions as of the date of
this press release and are subject to a number of risks and uncertainties, many of which are difficult to predict that could cause actual
results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements.
Important factors that could cause actual results to differ materially from current expectations include, among others, VCN-01&rsquo;s
differentiated mechanism of action transforming cancer therapy, Synthetic Biologics' and VCN&rsquo;s ability to reach clinical milestones
when anticipated including initiation of a Phase 2 study in patients with metastatic pancreatic adenocarcinoma in the fourth quarter of
2022 and a Phase 2/3 study in retinoblastoma in the second half of 2023 , Synthetic Biologics' ability to successfully combine and operate
the business of Synthetic Biologics and VCN, Synthetic Biologics' and VCN's product candidates demonstrating safety and effectiveness,
as well as results that are consistent with prior results; the ability to complete clinical trials on time and achieve the desired results
and benefits, continuing clinical trial enrollment as expected; the ability to obtain regulatory approval for commercialization of product
candidates or to comply with ongoing regulatory requirements, regulatory limitations relating to Synthetic Biologics' and VCN's ability
to promote or commercialize their product candidates for the specific indications, acceptance of product candidates in the marketplace
and the successful development, marketing or sale of Synthetic Biologics' and VCN's products, developments by competitors that render
such products obsolete or non-competitive, Synthetic Biologics' and VCN's ability to maintain license agreements, the continued maintenance
and growth of Synthetic Biologics' and VCN's patent estate, the ability to continue to remain well financed, and other factors described
in Synthetic Biologics' Annual Report on Form 10-K for the year ended December 31, 2021 and its other filings with the SEC, including
subsequent periodic reports on Forms 10-Q and current reports on Form 8-K. The information in this release is provided only as of the
date of this release, and Synthetic Biologics undertakes no obligation to update any forward-looking statements contained in this release
on account of new information, future events, or otherwise, except as required by law.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>For further information, please contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investor Relations:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chris Calabrese</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">LifeSci Advisors, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ccalabrese@lifesciadvisors.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">917-680-5608</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>syn-20220905.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.15c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWaaJabOdzZR+SYkxtmBybUl6fyAlf+4bKykBT982kZYJ -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:syn="http://syntheticbiologics.com/20220905" elementFormDefault="qualified" targetNamespace="http://syntheticbiologics.com/20220905">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://syntheticbiologics.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="syn-20220905_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="syn-20220905_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>syn-20220905_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.15c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>syn-20220905_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.15c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://syntheticbiologics.com/role/Cover" xlink:href="syn-20220905.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://syntheticbiologics.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>tm2225140d1_ex99-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2225140d1_ex99-1img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !* -X# 2(  A$! Q$!_\0
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MZ5?:W<>'?$.G:S+8V41EN;B&"8%Q&@Y9L'.!V!K(_8<\7^-/%_C3XD3>(_\
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M4R,'_:4AO?%7?VU/V0M9_94\;2.D=Q>>$-0F(TS43\V,C/DRD?=D'/LP&1W
M\/\ [4]Z_D*I@,PR7'..M*K![K1_)]4_N:/[DPU/+,_RY58<M6A47577HUT:
M^],_2?X#?\%7/#?C[6[;2_%VFCPM/<?(+\7'FV6[MOR T8/3)W =R!S7L?QJ
M_:]\#_!WX?W>LR>(-'U*Y$1-E96EXDTM[(1\B@(20I.,MT K\=?[4]Z/[4]Z
M_1,%XKYU1PLJ-:,:D^DWHUZI:.WR\[GYSC_ K):^,C7H2E3I_:@M4_1MW5^N
M_E8Z676?-D9CC+$GBN]_95:75_VF/ ,,.6?_ (2"RE(']U)D=O\ QU37CO\
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BE'%W'6;<1UE4S":Y8_#"*M&/HM;OS;;\[!1117T!\>?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140155726729200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Sep. 05, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep.  05,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-12584<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SYNTHETIC BIOLOGICS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000894158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">13-3808303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9605 Medical Center Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 270<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Rockville<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">417-4364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SYN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>tm2225140d1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="syn-20220905.xsd" xlink:type="simple"/>
    <context id="From2022-09-05to2022-09-05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
        </entity>
        <period>
            <startDate>2022-09-05</startDate>
            <endDate>2022-09-05</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-09-05to2022-09-05">0000894158</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-09-05to2022-09-05">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2022-09-05to2022-09-05">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2022-09-05to2022-09-05">2022-09-05</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2022-09-05to2022-09-05">SYNTHETIC BIOLOGICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-09-05to2022-09-05">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2022-09-05to2022-09-05">001-12584</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-09-05to2022-09-05">13-3808303</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-09-05to2022-09-05">9605 Medical Center Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2022-09-05to2022-09-05">Suite 270</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2022-09-05to2022-09-05">Rockville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-09-05to2022-09-05">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-09-05to2022-09-05">20850</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-09-05to2022-09-05">301</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-09-05to2022-09-05">417-4364</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2022-09-05to2022-09-05">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2022-09-05to2022-09-05">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2022-09-05to2022-09-05">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2022-09-05to2022-09-05">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2022-09-05to2022-09-05">Common stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-09-05to2022-09-05">SYN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-09-05to2022-09-05">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-09-05to2022-09-05">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M-J"XXIO@.WUT3.RC+*5\L8-I-' \2\1C'AHKP>!CR\<\CJT2</QS$'7*>]K
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MP %#TG1X#SY['R73>RHY_U=3_ 102P,$%     @ 6$$F59>*NQS     $P(
M  L   !?<F5L<R\N<F5L<YV2N6[#, Q ?\70GC 'T"&(,V7Q%@3Y 5:B#]@2
M!8I%G;^OVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4
M+!XUA]) 1-MC0[!:+#Y +AEFM[UD%J=SI%>(7->=I3W;+T]!;X"O.DQQ0FE(
M2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'<?VD-/I
MKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " !80295JL0B
M%C,!   B @  #P   'AL+W=O<FMB;V]K+GAM;(U1T6[", S\E2H?L!:T(0U1
M7D#;D*8-C8GWT+K4(HDKQX6-KY_;JAK27O:4W-FZW%T6%^+3@>B4?'D78FYJ
MD6:>IK&HP=MX1PT$G53$WHI"/J:Q8;!EK '$NW2:9;/46PQFN1BUMIS> A(H
M!"DHV1%[A$O\G7<P.6/$ SJ4[]ST=P<F\1C0XQ7*W&0FB35=7HCQ2D&LVQ5,
MSN5F,@SVP(+%'WK7F?RTA]@S8@\?5HWD9I:I8(4<I=_H]:UZ/(,N#Z@5>D(G
MP&LK\,S4-AB.G8RF2&]B]#V,YU#BG/]3(U45%K"FHO409.B1P74&0ZRQB28)
MUD-N5G0&[O+H YMRR"9JZJ8IGJ,.>%,.]D9/)508H'Q3F:B\]E-L.>F.7F=Z
M_S!YU!Y:YU;*O8=7LN48<?R>Y0]02P,$%     @ 6$$F520>FZ*M    ^ $
M !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<[61/0Z#, R%KQ+E #50
MJ4,%3%U8*RX0!?,C$A+%K@JW+X4!D#IT8;*>+7_OR4Z?:!1W;J"V\R1&:P;*
M9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!V#-DGNZ9HIP\_D-T==UI
M?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6HJ@R&8HJEG!:(.+)(&UI
M5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0    ( %A!)E5ED'F2&0$
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M;W!S+V%P<"YX;6Q02P$"% ,4    " !80295!'\.0.\    K @  $0
M        @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " !80295
MF5R<(Q &  "<)P  $P              @ '- 0  >&PO=&AE;64O=&AE;64Q
M+GAM;%!+ 0(4 Q0    ( %A!)E4#-:5_; 0  "L1   8              "
M@0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " !80295
MGZ ;\+$"  #B#   #0              @ &P#   >&PO<W1Y;&5S+GAM;%!+
M 0(4 Q0    ( %A!)E67BKL<P    !,"   +              "  8P/  !?
M<F5L<R\N<F5L<U!+ 0(4 Q0    ( %A!)E6JQ"(6,P$  "("   /
M      "  740  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !80295)!Z;
MHJT   #X 0  &@              @ '5$0  >&PO7W)E;',O=V]R:V)O;VLN
M>&UL+G)E;'-02P$"% ,4    " !8029599!YDAD!  #/ P  $P
M    @ &Z$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"   $
%%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2225140d1_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://syntheticbiologics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="tm2225140d1_8k.htm">tm2225140d1_8k.htm</File>
    <File>syn-20220905.xsd</File>
    <File>syn-20220905_lab.xml</File>
    <File>syn-20220905_pre.xml</File>
    <File>tm2225140d1_ex99-1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tm2225140d1_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "tm2225140d1_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "syn-20220905_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "syn-20220905_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "syn-20220905.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "syn",
   "nsuri": "http://syntheticbiologics.com/20220905",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2225140d1_8k.htm",
      "contextRef": "From2022-09-05to2022-09-05",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://syntheticbiologics.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2225140d1_8k.htm",
      "contextRef": "From2022-09-05to2022-09-05",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001104659-22-097701-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-22-097701-xbrl.zip
M4$L#!!0    ( %A!)E67(%&'00,  ! ,   0    <WEN+3(P,C(P.3 U+GAS
M9+5635/;,! ]MS/]#ZJOC&([-)2$!(:/H0,-I4.  I>.(LM!$T4RDDR2_OI*
MLIV$Q(0DM#[)J_?>[DJ[:S</1@,&GHE45/"6%U8"#Q".141YK^7==.!AY_CL
MS ,'^Y\^ O,T/T,(3BEA40.<" S/>"SVP \T( WPC7 BD19R#]PBEEJ+.*6,
M2' L!@DCFIB-S%,#U"IA#0,(5]"])3P2\N;J;*+[J'6B&KX_' XK7#RCH9!]
M5<%BL)I@1R.=JHE:, KR9S7Z!55X0MY"A[7AU]$5O>L1OINVT?8#_H70.>I>
M1G\>KK8Z]_V1'AR-NS=L)QX?LGCK2_?[N']T7=^M]A_NSS.7384?R0 !<QE<
MM3R;7Y[><+LB9,^O!D'HWUVT.P[G9<#&B%'>+X.']7K==[L%= $YZDI62&_[
M=KN+%)DHFUVZ!$^YTHCC%_A(3PBSX)J?;;Z TE+H3@:E!30B<SA%<*4GGGVS
M8?#5\.E+ 4T5["&43. Q4ETGFV\X. Q"N!T6%"7U(MP8RZ%0CQ.B2@G95AEM
MS"<$L]:/1%/<I8*)'L6N8"VI&M2#FFD[1@:$ZU,A!R<D1BDST3VEB-&8DL@#
M&LD>T;8"58(P65FW*&C$N3!U;YHOMUA;DE!3V,;PH6DKH"$%(]<F&6 7IN/>
M\F)A_K$P\\,#-&IYV=+J&76G&)&8<NK<YDT6 FA;*K7)FJ6C-/UY\(Q$JDAT
MR??=.I%$&9[+HVT,.3&'O$+"B.&4K<>9AE)*R0W%>4U/L&BD*Q(#UX -6QPM
M3U$[ KW<]BA);&QC#HM[^FTRJYBJ*1!6>4G_N8.?/XS<;R&!)%Y069@/1D0D
M1&IJ"GAF"&214VWI/V?< .M'><#_!QDSU%TW8T,A[#^FVK;ZLSGFC>)/.R5_
MG^^FILE62 WX0H,N&Y[9V&\+[*264.P;+'C0FF!8-9.F,E+1--)U@IB>P'I!
M%+P-@GAUA)=%H%XGV"7,EJNZ7OHY6.J^E.D3IE5A@5.M3<)9_'B\(QXGMD%
M+RX[TM*W0E8ZL#K5)4&]Q73O:J,2P2+E6HY=ABL6R2RE>'''L?;-S/\(K'8I
M!2N[$/MO\([B*/^UV#20UTNCZ6>:9OD74$L#!!0    ( %A!)E63BIA"_PH
M &R'   4    <WEN+3(P,C(P.3 U7VQA8BYX;6S-G5]3Z[@9QN\[T^^@36_:
MF1-"H-L9V,/N<')@)[,LL(1SMNU.9T>Q1?#@2*SL0/+M*]F68TMZ;4.GDKB
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M^8]GE/]*NG8UY?C%6X%/Q\>NN&Q>[WXHO-@*J*3-NP0?^/LF0.K!N*Y)AT-
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M0>RI05SXX]<0A[$JMY?H)AY8SF@Z*CIH]-P941?4F%D0,($:VXX,GP*/R5X
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M;4:9C43D(MC&:>\<.MV(FK: .=9JAO@3^DC%'#46P "F]-@.,T 2C;CIR@Q
MCS%9G!UPP $\";8=21T7.Y70.+Z\:CKQ-< K'I60/E@S*@("FM($$U 8>*
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MZ*@DX1=T9880A(TDY5O>9UOE7%L1*9562>**R!5NB?@+@E1HLV0_6Z#TW#G
MJ<O3;/8LH#1(Q?Y:J*!GI?6'%2_=1*L]GJLCX$1C172M+*V1-^ TJ<L55VXD
M</"5[=J)!NMFU$,R]>> HJA%0>86T9:+4F\2/YW/:B]80X4*1EXV<E2TJD%A
MGV9O>+V*!6ENID" $PDG'+OD0K777;%[V+IA#85+Q!U:O4%Q0=+*4H9PUGXU
M4<@E@&K*>37B)8H)J_?H*Q=E=0Y[9BH+JM>@WP]:S8JF5"-7$%8DJ)S%QUI4
MLJ1#5_%C[!X5&3'/\619VGCHL-Q:DK#NHO6E];@=');:3RFL78ZDW2MVL8X;
M)*T\RV+(U,8$&[<_SC+R-5>"O!)9XEL*V+N=X,-"1^:"PD];4>B)R-7;=[OV
M>ZZNBT2)T6YCF=A8S1J![7*>G:Y$3R2=T$^0,P"=5% Z*M!A;U-M;FCW_W93
MM-Z_W7J"_1)\<+7"E5*%TTFYC#6D68Z%V"+8(D2!\W,QRMH+CH&;8-:66@I^
M#<7/"#62*KV!*,H\=KV)^]Q^E6-5'TTL-T4 :>?R59G9%(F*Q*OU%S8JZ6,+
M/]+=8M6L\$P2P>*&[-1!LT47&X(DG"9@'O'SUJ?I<U"]:>2^I5H_<KZ2ET;%
M_K-/S4^.W,?J.,^5<+4]\^RI/IW0AYJG/.$A-6V?,ZD7<B0&D63'\50:1;'L
MQ<7I<R8XBBJV_E<"V@V\L2?=54"?+^5[W9^#U[]T@E>O.[_\#72N_OF+KRBX
M[AZP3RX3VV<7B,*?3_WUX6+HW7^78YO^7(G[^R7T9T[^%U!+ 0(4 Q0    (
M %A!)E67(%&'00,  ! ,   0              "  0    !S>6XM,C R,C Y
M,#4N>'-D4$L! A0#%     @ 6$$F59.*F$+_"@  ;(<  !0
M ( !;P,  '-Y;BTR,#(R,#DP-5]L86(N>&UL4$L! A0#%     @ 6$$F5?5H
ME#E;!P  U%@  !0              ( !H X  '-Y;BTR,#(R,#DP-5]P<F4N
M>&UL4$L! A0#%     @ 6$$F5=9ZQ'[5%@  #7T  !(              ( !
M+18  '1M,C(R-3$T,&0Q7SAK+FAT;5!+ 0(4 Q0    ( %A!)E6O@]G"!!(
M .U$   6              "  3(M  !T;3(R,C4Q-#!D,5]E>#DY+3$N:'1M
64$L%!@     %  4 1@$  &H_      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
